Year: 2018
Type: dissertation
Abstract: New breakthroughs in cancer research have yielded potentially curative cancer therapies, including for urologic malignancies. However, while these developments spell new hope for many patients, a complete understanding of the disease is still far. Biomarkers capable of predicting the natural history of cancer disease are increasingly needed in order to tailor medical intervention. Cancer, a cellular “demonic evil growth”, is driven by the acquisition of multiple molecular abnormalities, but it is exclusively dependent on molecular processes that lead to the maintenance of telomeres. In neoplastic cells, the process of maintaining telomeres is controlled by telomerase in 85-90% of the cases, and by alternative (non-telomerase- -dependent) mechanisms in the other 10% to 15%. Both mechanisms are responsible for unlimited cellular self-renewal (a hallmark of cancer) (Hanahan & Weinberg, 2011). The role of telomeres is well established as an important driving force in preventing chromosomal and genomic instability. However, the complete understanding of mechanisms responsible for telomere maintenance and their potential diagnostic and prognostic value remain uncertain. The study of the mechanisms by which telomeres are maintained in cancer cells will allow a better understanding of the biology of telomeres in cancer and may recognize possible therapeutic targets that might prevent genetic instability and cancer-cell immortalization. Simultaneously, knowing that the progression of cancer disease does not occur without cellular immortality, the mechanisms responsible for the maintenance of telomeres might provide important information in terms of the natural history of the different oncological diseases and potentially be used as cancer biomarkers. Consequently, the main objective of our study was to examine the prevalence of different telomere maintenance mechanisms [either by their contribution to telomerase activation or in a telomerase-independent manner (alternative lengthening of telomeres – ALT] and their diagnostic and prognostic properties in urological malignancies, such as prostate, bladder and testicular cancer. In what concerns to prostate cancer, the mechanisms leading to telomerase activation have not been yet described. In our study, we analyzed the levels of DNA methylation of a specific region within the telomerase (TERT) promoter, composed of 5 CpG sites and which our group defined as THOR (TERT Hypermethylated Oncological Region). We observed, for the first time, that differential methylation in this region has diagnostic properties and is associated with the disease aggressiveness. In addition, THOR showed prognostic properties and, whenever hypermethylated, it was a risk factor for biochemical recurrence in patients with lower-risk prostate cancer (HR: 3.68; 95% CI 1.18 to 11.50). Contrarily to prostate cancer, a specific TERT regulator mechanism was previously identified in urothelial bladder cancer (UBC). UBC are known to undergo telomerase reactivation in up to 90% of the cases and non-coding mutations of the TERT promoter (TERTpMut) have been causally implicated. In our study, we questioned not only the role of these genetic alterations, but also the involvement of epigenetic mechanisms (THOR methylation) in the expression of telomerase and its association with clinical outcomes. Our results demonstrated that TERTpMut are early events in UBC and THOR methylation is a dynamic mechanism involved in the tumorigenesis influencing the history of the disease. Interestingly, we have found that genetic and epigenetic mechanisms may be simultaneously present in the same tumor and, when combined, the resulting effect leads to increased telomerase expression and an increased risk for disease progression. Therefore, the combined molecular alterations of the TERT promoter (THOR hypermethylated, THORhigh and TERTpMut) comprise a risk factor for disease recurrence (HR:5.12, 95% CI 2.3 to 11.3 p<0.0001) and disease progression (HR: 3.92; 95% CI 1.2 to 13.0, p= 0.026) in non-muscle invasive bladder cancers (NMIBC). These results highlight important aspects: the frequency of TERT promoter mutations is quite high and the combined action of the genetic and epigenetic mechanisms on the TERT promoter provides a new and important insight into the biology of telomeres with implications for clinical outcomes. Testicular cancer is not as common as prostate and bladder cancer, and characteristically affects younger patients. Like the other tumors studied, it is also known to be a TERT- -dependent tumor, but with unique and distinct characteristics – it is a heterogeneous germ cell tumor (inter- and intra-tumoral heterogeneity) and displays alternative mechanisms to maintain telomeres (ALT). In this chapter, we have chosen a more comprehensive methodology, including not only the study of telomere maintenance mechanisms. After reflecting on the clinical needs for biomarkers at different stages of testicular cancer, we focused our attention on the identification of biomarkers for advanced nonseminomatous disease since there is an imperative need to identify biomarkers capable of predicting the histology of post-chemotherapy residual lesions and sparing these patients from significant morbid surgeries. Therefore, our first approach focused on the creation of a clinical model capable of predicting the presence of benign lesions (necrosis and/or fibrosis). Our model (Princess Margaret Model) was based on the exclusive use of clinical variables (presence of teratoma histology in the primary, AFP, dimension of residual disease and its variations with chemotherapy treatment) and allows predicting the presence of benign histology with high accuracy (C index 0.82) and sensitivity (99.3%), improving previous results by other groups. Subsequently, we focused our attention on the mechanisms of telomere maintenance in testicular germ cell tumors (TGCT) and its association with histological heterogeneity and clinical outcomes. These tumors are characteristically heterogeneous and telomerase expression levels are simultaneously elevated in tumor and normal tissues (without cancer cells) in contradiction to other types of cancer. The expression of telomerase is dissimilarly elevated according to histology (elevated in embryonal carcinomas and absent in teratomas, comprising inter-tumoral heterogeneity) and does not depend on mechanisms associated with cancer for its activation (mutations of the TERT promoter and THOR are absent). The most striking finding was related to the concomitant recruitment of telomerase and alternative mechanisms of telomere maintenance (ALT) in some nonseminoma lesions. This observation suggests intra-tumor heterogeneity and allows us to propose a hypothesis for the maturation of testicular lesions implicating telomere biology; a continuous process between telomerase activation and alternative mechanisms that may accompany the maturation process of embryonic lesions into teratomas. Lastly, with emphasis on the demands of 21st century Medicine, we have questioned the properties of a serum marker – liquid biopsies – in patients with advanced testicular nonseminomatous germ cell tumors (NSGCT). As for the clinical model, we were interested in evaluating the ability to predict the histology of residual retroperitoneal disease. We interrogated the role of serum epigenetic markers (miRNA) as predictive tools for viable residual disease after chemotherapy. MiR-371a-3p demonstrated high discriminative capacity for viable disease (AUC 0.874, 95% CI 0.77-0.97). This is the first molecular, non-invasive method to determine the presence of viable disease post-chemotherapy in NSGCT patients with negative findings on traditional serum protein biomarkers (AFP, HCG) and residual disease on imaging. Future prospective validation of this discover might change the current paradigm of advanced testicular cancer treatment. The results obtained in this thesis provide important information in terms of telomere biology and highlight the role of the mechanisms responsible for its maintenance as biomarkers with diagnostic and prognostic properties. These results allow a better understanding of tumor biology and provide insight about the interaction between mechanisms related to telomerase activation and alternative mechanisms of telomere maintenance, which might unveil possible means to prevent the acquisition of aberrant self-renewal capacity that characterizes cancer.
Author: Ricardo Leão
Institution: University of Coimbra
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Keywords: telomere maintenance, genitourinary cancer, telomerase, alternative lengthening of telomeres, prostate cancer, bladder cancer, testicular cancer, prognostic factors, diagnostic biomarkers, biochemical recurrence, cancer cell immortality, genomic instability, therapeutic target, disease aggressiveness, DNA methylation biomarkers, prognostic gene signature
Open Access status: green
OpenAlex ID: W3137001152
